Appeal No. 95-1364
Application No. 07/919,287
1. A method of treating a viral condition caused by an enveloped virus, said
method comprising using a therapeutically effective amount of a compound
selected from the group consisting of a substituted benzene, wherein said benzene
1 2 1 2 1
comprises a 2-R , 3-R -1-OX , 4-OX compound where at least one of R and
2 1 2
R include a carbon linkage to the benzene ring and OX and OX are
simultaneously hydroxy.
14. A method of treating a viral condition caused by an enveloped virus, said
method comprising using a therapeutically effective amount of a compound having
an IC of less than 10 M in the INF assay, wherein said compound comprises-3
50
1 2 1
a substituted benzene, wherein said benzene comprises a 2-R , 3-R -1-OX , 4-
2 1 2
OX compound where at least one of R and R include a carbon linkage to the
1 2
benzene ring and OX and OX are simultaneously hydroxy.
23. A method of treating a viral condition caused by an enveloped virus, said
method comprising using a therapeutically effective amount of a compound which
binds near the hinge region or near the stem region of hemagglutinin.
26. A method of treating a viral condition wherein the viral condition is caused
by a virus having a fusion protein which has a native, non-fusogenic conformation
and a second, fusogenic conformation, the method comprising using a
therapeutically effective amount of a compound which binds to the fusion protein
in the native conformation and reduces the ability of the fusion protein to adopt the
fusogenic conformation.
As we understand the subject matter of claims 1 and 14, the substituted benzene compound set forth in
these claim is represented by the following structural formula:
OH
1 1
R
6
2
5
3
2
R
4
OH
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007